This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

To access the live and subsequently archived webcast of the presentations, go to the
Investor Relations section of the company's website at
http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic HealthGenomic Health, Inc. (NASDAQ:
GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The company's lead product, the
Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive
breast cancer and has been shown to predict the likelihood of recurrence in
ductal carcinoma in situ (DCIS). In addition to this widely adopted test,
Genomic Health provides the
Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with
stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of March 31, 2013, more than 19,000 physicians in over 70 countries had ordered more than 350,000 Oncotype DX tests. Genomic Health has a robust
pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in breast, colon and prostate cancers. The company is based in
Redwood City, California with European headquarters in Geneva, Switzerland.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the demand for the company's tests; the ability of any potential tests the company may develop to optimize cancer treatment and the Company's ability to launch new tests in new markets and expand internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.